74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
REGENXBIO Inc
Closed
Sector Healthcare
7.27 -1.09
Overview
Share price change
24h
Min
7.26
Max
7.32
Income | -6.6M -60M |
|---|---|
Sales | 1.9M 24M |
EPS | -1.17 |
Profit margin | -246.299 |
Employees | 344 |
EBITDA | -6.3M -55M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +275.38 upside |
Next Earnings | 25 Feb 2025 |
|---|
Market Cap | 370M |
|---|---|
Previous open | 8.36 |
Previous close | 7.27 |
News Sentiment
By Acuity
56%
44%
317 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
REGENXBIO Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
REGENXBIO Inc Forecast
Price Target
By TipRanks
275.38% upside
12 Months Forecast
Average 27.29 USD 275.38%
High 40 USD
Low 14 USD
Based on 7 Wall Street analysts offering 12 month price targets forREGENXBIO Inc - Dist in the last 3 months.
Sentiment
By Acuity
317 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
